{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:48:59Z","timestamp":1789429739708,"version":"build-2803163510"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019446","name":"Medical and Health Science and Technology Development Project of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019446","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574790"],"award-info":[{"award-number":["82574790"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.tranon.2026.102666","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:03:08Z","timestamp":1767895388000},"page":"102666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mechanistic and translational insights into plant-derived natural products in preclinical multiple myeloma research: Current evidence"],"prefix":"10.1016","volume":"64","author":[{"given":"Lulu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changnian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102666_bib0001","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.tranon.2026.102666_bib0002","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/NHH.0000000000001249","article-title":"Multiple myeloma","volume":"42","author":"Vrtis","year":"2024","journal-title":"Home Healthc. Now"},{"key":"10.1016\/j.tranon.2026.102666_bib0003","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3390\/cancers13112712","article-title":"Rapid progress in immunotherapies for multiple myeloma: an updated comprehensive review","volume":"13","author":"Nishida","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102666_bib0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4155\/ppa-2021-0027","article-title":"Baicalein: promising therapeutic applications with special reference to published patents","volume":"11","author":"Gupta","year":"2022","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.tranon.2026.102666_bib0005","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2004-10-3915","article-title":"Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells","volume":"105","author":"Ma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102666_bib0006","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-0609.2009.01365.x","article-title":"Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells","volume":"84","author":"Liu","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102666_bib0007","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/mol.113.088609","article-title":"Molecular pharmacology of ABCG2 and its role in chemoresistance","volume":"84","author":"Stacy","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102666_bib0008","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.7314\/APJCP.2013.14.12.7179","article-title":"Scutellaria extract decreases the proportion of side population cells in a myeloma cell line by down-regulating the expression of ABCG2 protein","volume":"14","author":"Lin","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.tranon.2026.102666_bib0009","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.fitote.2014.01.019","article-title":"Baicalein decreases side population proportion via inhibition of ABCG2 in multiple myeloma cell line RPMI 8226 in vitro","volume":"94","author":"Gu","year":"2014","journal-title":"Fitoterapia"},{"key":"10.1016\/j.tranon.2026.102666_bib0010","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.12659\/MSM.907058","article-title":"Baicalein inhibits proliferation of myeloma U266 cells by downregulating IKZF1 and IKZF3","volume":"24","author":"Liu","year":"2018","journal-title":"Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.tranon.2026.102666_bib0011","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.biopha.2018.09.024","article-title":"Scutellarein selectively targets multiple myeloma cells by increasing mitochondrial superoxide production and activating intrinsic apoptosis pathway","volume":"109","author":"Shi","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tranon.2026.102666_bib0012","doi-asserted-by":"crossref","unstructured":"Gu, Y., Zheng, Q., Fan, G., Liu, R., 2022. Advances in anti-cancer activities of flavonoids in scutellariae radix: perspectives on mechanism. 23, 11042.","DOI":"10.3390\/ijms231911042"},{"key":"10.1016\/j.tranon.2026.102666_bib0013","article-title":"The most recent progress of baicalein in its anti-neoplastic effects and mechanisms","volume":"176","author":"Lei","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.tranon.2026.102666_bib0014","doi-asserted-by":"crossref","unstructured":"Wang, R., Wang, C., Lu, L., Yuan, F., He, F.J.P.R., 2024. Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: a comprehensive review with future perspectives. 199, 107032.","DOI":"10.1016\/j.phrs.2023.107032"},{"key":"10.1016\/j.tranon.2026.102666_bib0015","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.3390\/molecules29163886","article-title":"Artemisinin and its derivatives as potential anticancer agents","volume":"29","author":"Wen","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.tranon.2026.102666_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115000","article-title":"A comprehensive overview of Artemisinin and its derivatives as anticancer agents","volume":"247","author":"Zeng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tranon.2026.102666_bib0017","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12185-009-0409-z","article-title":"Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2\/0 myeloma cells through affecting NF\u00a6\u00caB p65","volume":"90","author":"Li","year":"2009","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.tranon.2026.102666_bib0018","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/ejh.12176","article-title":"Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate","volume":"91","author":"Holien","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102666_bib0019","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.18632\/oncotarget.1847","article-title":"Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis","volume":"5","author":"Papanikolaou","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2026.102666_bib0020","first-page":"2562","article-title":"Dihydroartemisinin treatment of multiple myeloma cells causes activation of c-Jun leading to cell apoptosis","volume":"15","author":"Wang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.tranon.2026.102666_bib0021","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6096391","article-title":"Dihydroartemisinin modulates apoptosis and autophagy in multiple myeloma through the P38\/MAPK and wnt\/\u00a6\u00c2\u00a9\\Catenin Signaling pathways","volume":"2020","author":"Wu","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.tranon.2026.102666_bib0022","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.cad.0000224443.85834.32","article-title":"Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion","volume":"17","author":"Wu","year":"2006","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.tranon.2026.102666_bib0023","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12185-010-0697-3","article-title":"Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells","volume":"92","author":"Chen","year":"2010","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.tranon.2026.102666_bib0024","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2020.00767","article-title":"Dihydroartemisinin induces growth arrest and overcomes dexamethasone resistance in multiple myeloma","volume":"10","author":"Chen","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2026.102666_bib0025","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.7150\/ijms.86409","article-title":"Artesunate induces ferroptosis by inhibiting the nuclear localization of SREBP2 in myeloma cells","volume":"20","author":"Liang","year":"2023","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.tranon.2026.102666_bib0026","first-page":"3085","article-title":"First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone","volume":"52","author":"Nagelschmitz","year":"2008","journal-title":"Chemotherapy"},{"key":"10.1016\/j.tranon.2026.102666_bib0027","doi-asserted-by":"crossref","unstructured":"Gautam, A., Ahmed, T., Batra, V., Paliwal, J.J.C.d.m., 2009. Pharmacokinetics and pharmacodynamics of endoperoxide antimalarials. 10, 289-306.","DOI":"10.2174\/138920009787846323"},{"key":"10.1016\/j.tranon.2026.102666_bib0028","first-page":"1","article-title":"Artemisinin-type drugs for the treatment of hematological malignancies","volume":"87","author":"Mancuso","year":"2021","journal-title":"Pharmacology"},{"key":"10.1016\/j.tranon.2026.102666_bib0029","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3390\/nu11102376","article-title":"Curcumin and cancer","volume":"11","author":"Giordano","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.tranon.2026.102666_bib0030","first-page":"1053","article-title":"Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor\u00a8C\u00a6\u00caB and I\u00a6\u00caB\u00a6\u00c1 kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood","volume":"101","author":"Bharti","year":"2003","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.tranon.2026.102666_bib0031","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.4049\/jimmunol.171.7.3863","article-title":"Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells","volume":"171","author":"Bharti","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2026.102666_bib0032","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.molonc.2008.09.006","article-title":"Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells","volume":"2","author":"Park","year":"2008","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.tranon.2026.102666_bib0033","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/15384047.2014.986997","article-title":"Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups","volume":"16","author":"Gomez-Bougie","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.tranon.2026.102666_bib0034","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3892\/ol.2015.2946","article-title":"A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line","volume":"9","author":"Li","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.tranon.2026.102666_bib0035","first-page":"1108","article-title":"Curcumin-induced promoter hypermethylation of the mammalian target of rapamycin gene in multiple myeloma cells","volume":"17","author":"Chen","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.tranon.2026.102666_bib0036","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2174\/1381612823666170317164639","article-title":"Effect and mechanism of curcumin on EZH2-miR-101 regulatory feedback loop in multiple myeloma","volume":"24","author":"Wu","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.tranon.2026.102666_bib0037","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00277-009-0831-6","article-title":"Reversal of multidrug resistance by curcumin through FA\/BRCA pathway in multiple myeloma cell line MOLP-2\/R","volume":"89","author":"Xiao","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.tranon.2026.102666_bib0038","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.3390\/ijms13044831","article-title":"Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-\u00a6\u00caB\/JNK","volume":"13","author":"Bai","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102666_bib0039","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tiv.2017.12.001","article-title":"Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-\u00a6\u00caB pathways","volume":"47","author":"Allegra","year":"2018","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.tranon.2026.102666_bib0040","doi-asserted-by":"crossref","unstructured":"Golombick, T., Diamond, T.H., Manoharan, A., Ramakrishna, R., 2012. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. 87, 455-460.","DOI":"10.1002\/ajh.23159"},{"key":"10.1016\/j.tranon.2026.102666_bib0041","first-page":"3719","article-title":"Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma","volume":"31","author":"Kudo","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tranon.2026.102666_bib0042","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1039\/c3ob40595h","article-title":"Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma","volume":"11","author":"Liu","year":"2013","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.tranon.2026.102666_bib0043","doi-asserted-by":"crossref","first-page":"159","DOI":"10.18632\/oncotarget.28558","article-title":"GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells","volume":"15","author":"Booth","year":"2024","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2026.102666_bib0044","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202302030","article-title":"Curcumin\u00a8CBioavailability enhancement by prodrug approach and novel formulations","volume":"21","author":"Chelimela","year":"2024","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.tranon.2026.102666_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27010167","article-title":"Nrf2 regulation by curcumin: molecular aspects for therapeutic prospects","volume":"27","author":"Shahcheraghi","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.tranon.2026.102666_bib0046","doi-asserted-by":"crossref","unstructured":"Entezari, M., Tayari, A., Paskeh, M.D.A., Kheirabad, S.K., Naeemi, S., Taheriazam, A., Dehghani, H., Salimimoghadam, S., Hashemi, M., Mirzaei, S.J.J.o.T., Medicine, C., 2024. Curcumin in treatment of hematological cancers: promises and challenges. 14, 121-134.","DOI":"10.1016\/j.jtcme.2023.10.004"},{"key":"10.1016\/j.tranon.2026.102666_bib0047","doi-asserted-by":"crossref","unstructured":"Mirzaei, H., Bagheri, H., Ghasemi, F., Khoi, J.M., Pourhanifeh, M.H., Heyden, Y.V., Mortezapour, E., Nikdasti, A., Jeandet, P., Khan, H.J.A.-C.A.i.M.C.-A.-C.A., 2021. Anti-cancer activity of curcumin on multiple myeloma. 21, 575-586.","DOI":"10.2174\/1871520620666200918113625"},{"key":"10.1016\/j.tranon.2026.102666_bib0048","article-title":"Celastrol as an emerging anticancer agent: current status, challenges and therapeutic strategies","volume":"163","author":"Wang","year":"2023","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"key":"10.1016\/j.tranon.2026.102666_bib0049","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1476-5381.2011.01449.x","article-title":"Celastrol inhibits proliferation and induces chemosensitization through down\u00a9\\regulation of NF\u00a9\\\u00a6\u00caB and STAT3 regulated gene products in multiple myeloma cells","volume":"164","author":"Kannaiyan","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102666_bib0050","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1007\/s10495-011-0629-6","article-title":"Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K\/Akt signaling pathways","volume":"16","author":"Kannaiyan","year":"2011","journal-title":"Apoptosis"},{"key":"10.1016\/j.tranon.2026.102666_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095846","article-title":"NF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosis","volume":"9","author":"Ni","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2026.102666_bib0052","first-page":"1117","article-title":"Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-\u03bab pathway","volume":"39","author":"Tozawa","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.tranon.2026.102666_bib0053","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000354770","article-title":"Celastrol inhibits lipopolysaccharide-induced angiogenesis by suppressing TLR4-triggered nuclear factor-kappa B activation","volume":"131","author":"Ni","year":"2014","journal-title":"Acta Haematol."},{"key":"10.1016\/j.tranon.2026.102666_bib0054","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejphar.2019.03.036","article-title":"Celastrol induce apoptosis of human multiple myeloma cells involving inhibition of proteasome activity","volume":"853","author":"Zhong","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102666_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040616","article-title":"Disruption of proteostasis by natural products and synthetic compounds that induce pervasive unfolding of proteins: therapeutic implications","volume":"16","author":"Vilaboa","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tranon.2026.102666_bib0056","first-page":"1884","article-title":"Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation","volume":"55","author":"Jin","year":"2023","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.tranon.2026.102666_bib0057","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/abbs\/gmx021","article-title":"Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1\/2 and IL-6\/STAT3 pathways in vitro and in vivo","volume":"49","author":"Hu","year":"2017","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.tranon.2026.102666_bib0058","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3389\/fphar.2018.00365","article-title":"Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma","volume":"9","author":"Shanmugam","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102666_bib0059","article-title":"Celastrol: a review of useful strategies overcoming its limitation in anticancer application","volume":"11","author":"Shi","year":"2020","journal-title":"J. Front. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102666_bib0060","article-title":"Recent advances in drug delivery of celastrol for enhancing efficiency and reducing the toxicity","volume":"15","author":"Sun","year":"2024","journal-title":"J. Front. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102666_bib0061","doi-asserted-by":"crossref","first-page":"10385","DOI":"10.2147\/IJN.S277645","article-title":"Gambogic acid as a candidate for cancer therapy: a review","volume":"15","author":"Liu","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.tranon.2026.102666_bib0062","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2141.2011.08888.x","article-title":"Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells","volume":"155","author":"Chauhan","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102666_bib0063","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3892\/ol.2012.634","article-title":"Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS","volume":"3","author":"Yang","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.tranon.2026.102666_bib0064","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.exphem.2014.07.261","article-title":"Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways","volume":"42","author":"Pandey","year":"2014","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.tranon.2026.102666_bib0065","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/cas.12458","article-title":"Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1\u03b1\/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase\/Akt\/mammalian target protein of rapamycin pathway in multiple myeloma cells","volume":"105","author":"Wang","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2026.102666_bib0066","doi-asserted-by":"crossref","unstructured":"Li, M., Su, F., Zhu, M., Zhang, H., Wei, Y., Zhao, Y., Li, J., Lv, S.J.M., 2022. Research progress in the field of gambogic acid and its derivatives as antineoplastic drugs. 27, 2937.","DOI":"10.3390\/molecules27092937"},{"key":"10.1016\/j.tranon.2026.102666_bib0067","doi-asserted-by":"crossref","unstructured":"Liu, Y., Chen, Y., Lin, L., Li, H.J.I.J.o.N., 2020. Gambogic acid as a candidate for cancer therapy: a review. 10385-10399.","DOI":"10.2147\/IJN.S277645"},{"key":"10.1016\/j.tranon.2026.102666_bib0068","doi-asserted-by":"crossref","unstructured":"Fahmy, S.A., Elghanam, R., Rashid, G., Youness, R.A., Sedky, N.K.J.R.a., 2024. Emerging tendencies for the nano-delivery of gambogic acid: a promising approach in oncotherapy. 14, 4666-4691.","DOI":"10.1039\/D3RA08042K"},{"key":"10.1016\/j.tranon.2026.102666_bib0069","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/10408398.2016.1263597","article-title":"Resveratrol as an anti-cancer agent: a review","volume":"58","author":"Rauf","year":"2018","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.tranon.2026.102666_bib0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1535-7163.71.3.1","article-title":"Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis","volume":"3","author":"Jazirehi","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2026.102666_bib0071","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1182\/blood-2006-02-003988","article-title":"Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-\u00a6\u00caB\u00a8cregulated antiapoptotic and cell survival gene products in human multiple myeloma cells","volume":"109","author":"Bhardwaj","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102666_bib0072","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1745-7254.2006.00343.x","article-title":"Resveratrol as a novel agent for treatment of multiple myeloma with matrix metalloproteinase inhibitory activity","volume":"27","author":"SUN","year":"2006","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.tranon.2026.102666_bib0073","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cancergencyto.2005.06.016","article-title":"Resveratrol downregulates the constitutional activation of nuclear factor-\u00a6\u00caB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis","volume":"165","author":"Sun","year":"2006","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.tranon.2026.102666_bib0074","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.exphem.2011.06.007","article-title":"Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells","volume":"39","author":"Wang","year":"2011","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.tranon.2026.102666_bib0075","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3389\/fphar.2018.00334","article-title":"Resveratrol sensitizes carfilzomib-induced apoptosis via promoting oxidative stress in multiple myeloma cells","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102666_bib0076","first-page":"6257","article-title":"Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma","volume":"15","author":"Jin","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.tranon.2026.102666_bib0077","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.biopha.2018.08.003","article-title":"Resveratrol inhibits proliferation, migration and invasion of multiple myeloma cells via NEAT1-mediated wnt\/\u00a6\u00c2-catenin signaling pathway","volume":"107","author":"Geng","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tranon.2026.102666_bib0078","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262212","article-title":"A novel pro-oxidant combination of resveratrol and copper reduces transplant related toxicities in patients receiving high dose melphalan for multiple myeloma (RESCU 001)","volume":"17","author":"Agarwal","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2026.102666_bib0079","doi-asserted-by":"crossref","unstructured":"Staskiewicz, A., Wong, E., Tucker, M., Farhin, R., Park, J., Saade, R., Alkhazali, T., Dang, T., Wang, X., 2023. Cytotoxic and apoptotic effects of pinostilbene and bortezomib combination treatment on Human Multiple myeloma cells. 24, 12590.","DOI":"10.3390\/ijms241612590"},{"key":"10.1016\/j.tranon.2026.102666_bib0080","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400269","article-title":"TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: novel insights about resveratrol pleiotropic effects","volume":"357","author":"Rocca","year":"2024","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.tranon.2026.102666_bib0081","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/antiox8080244","article-title":"Strategies to improve resveratrol systemic and topical bioavailability: an update","volume":"8","author":"Intagliata","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.tranon.2026.102666_bib0082","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3892\/mmr.2016.5475","article-title":"Inhibition of multiple myeloma cell proliferation by ginsenoside Rg3 via reduction in the secretion of IGF-1","volume":"14","author":"Li","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.tranon.2026.102666_bib0083","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.3892\/mmr.2015.3802","article-title":"Ginsenoside Rg3 induces apoptosis in human multiple myeloma cells via the activation of Bcl-2-associated X protein","volume":"12","author":"Luo","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.tranon.2026.102666_bib0084","article-title":"Ginsenoside Rg1 inhibits multiple myeloma and overcomes bortezomib resistance through AMPK-mTOR pathway","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.tranon.2026.102666_bib0085","article-title":"Therapeutic effect and molecular mechanism of the ultra-low molecule compound K on multiple myeloma","volume":"180","author":"Lee","year":"2024","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"key":"10.1016\/j.tranon.2026.102666_bib0086","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1158\/1535-7163.MCT-04-0277","article-title":"Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-\u00a6\u00caB signal pathways","volume":"4","author":"Ikezoe","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2026.102666_bib0087","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0254-6272(16)30031-0","article-title":"Inhibitory effect of oridonin on proliferation of RPMI8226 cells and the possible underlying mechanism","volume":"36","author":"Yaning","year":"2016","journal-title":"J. Tradit. Chin. Med."},{"key":"10.1016\/j.tranon.2026.102666_bib0088","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/aps.2011.143","article-title":"Autophagy counteracts apoptosis in human multiple myeloma cells exposed to oridonin in vitro via regulating intracellular ROS and SIRT1","volume":"33","author":"Zeng","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.tranon.2026.102666_bib0089","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.3892\/mmr.2017.6213","article-title":"Proteomic analysis of oridonin-induced apoptosis in multiple myeloma cells","volume":"15","author":"Zhao","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.tranon.2026.102666_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116748","article-title":"Chemical constituents, pharmacological action, antitumor application, and toxicity of strychnine semen from Strychnons pierriana AW Hill.: a review","volume":"317","author":"Liu","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.tranon.2026.102666_bib0091","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12013-012-9492-5","article-title":"Strychnos nux-vomica root extract induces apoptosis in the human multiple myeloma cell line\u00a1\u00aaU266B1","volume":"66","author":"Rao","year":"2013","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.tranon.2026.102666_bib0092","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.fct.2008.10.027","article-title":"Anti-proliferative and cytotoxic effects of Strychnos nux-vomica root extract on human multiple myeloma cell line\u00a8CRPMI 8226","volume":"47","author":"Rao","year":"2009","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.tranon.2026.102666_bib0093","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3892\/mmr.2012.920","article-title":"Effects of brucine on bone metabolism in multiple myeloma","volume":"6","author":"Ma","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.tranon.2026.102666_bib0094","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.3892\/ol.2016.5048","article-title":"Plumbagin inhibits cell proliferation and promotes apoptosis in multiple myeloma cells through inhibition of the PI3K\/Akt-mTOR pathway","volume":"12","author":"Wu","year":"2016","journal-title":"Oncol. lett."},{"key":"10.1016\/j.tranon.2026.102666_bib0095","unstructured":"Lin, S., Shen, C., Jiang, J., Wu, L., Dai, T., Qian, W., Meng, H., 2013. Apoptosis of multiple myeloid cells induced by polysaccharides extracts from Hedyotis diffusa and its mechanism. 34, 337-340."},{"key":"10.1016\/j.tranon.2026.102666_bib0096","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.3399","article-title":"Icaritin suppresses multiple myeloma, by inhibiting IL-6\/JAK2\/STAT3","volume":"6","author":"Zhu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2026.102666_bib0097","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/kjm2.12504","article-title":"Icaritin-elevated circ_0000190 suppresses the malignant progression of multiple myeloma by targeting miR-301a","volume":"38","author":"Zhu","year":"2022","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.tranon.2026.102666_bib0098","doi-asserted-by":"crossref","first-page":"14942","DOI":"10.1021\/acs.jmedchem.1c00087","article-title":"Design, synthesis, and biological evaluation of icaritin derivatives as novel putative DEPTOR inhibitors for multiple myeloma treatment","volume":"64","author":"Hou","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tranon.2026.102666_bib0099","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","article-title":"DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival","volume":"137","author":"Peterson","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102666_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2018.05.038","article-title":"Formononetin-induced oxidative stress abrogates the activation of STAT3\/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model","volume":"431","author":"Kim","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tranon.2026.102666_bib0101","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/biom9070262","article-title":"Formononetin regulates multiple oncogenic signaling cascades and enhances sensitivity to bortezomib in a multiple myeloma mouse model","volume":"9","author":"Kim","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.tranon.2026.102666_bib0102","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12672-024-01076-z","article-title":"Anti-tumor effect of dandelion flavone on multiple myeloma cells and its mechanism","volume":"15","author":"Gui","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.tranon.2026.102666_bib0103","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/1440-1681.13805","article-title":"Ginsenoside Rh4 inhibits the malignant progression of multiple myeloma and induces ferroptosis by regulating SIRT2","volume":"50","author":"Ying","year":"2023","journal-title":"Clin. Exp. Pharmacol. Physiol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:56:10Z","timestamp":1781178970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":103,"alternative-id":["S1936523326000033"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102666","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic and translational insights into plant-derived natural products in preclinical multiple myeloma research: Current evidence","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102666","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102666"}}